Clinical Trial

Study on Preliminary Safety and Efficacy of the ARC-IM Therapy to Alleviate Locomotor Deficits in People With Parkinson's Disease

Study acronym: SPARKL
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this clinical trial is to assess the preliminary safety and efficacy of the ARC-IM spinal cord stimulation therapy in alleviating locomotor deficits in individuals with Parkinson's disease. The ARC-IM Therapy employs epidural electrical stimulation (EES) to modulate leg muscle recruitment, with the aim of improving mobility deficits. The ultimate goal is to enhance the quality of life of people with Parkinson's disease.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-03-05; most recent amendment 2026-06-03.
Status change: Not Yet Recruiting → Recruiting 2024-03-08
Trial Details
NCT Number NCT06295614
Lead Sponsor Ecole Polytechnique Fédérale de Lausanne
Conditions Parkinson Disease
Enrollment 6 participants
Start Date 2024-02-14
Primary Completion 2029-04-01 (estimated)
Study Completion 2029-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-04